On March 30, 2021 VBL Therapeutics (Nasdaq: VBLT) reported that it will host a virtual R&D Day for analysts and investors beginning at 10:00am ET on Tuesday, April 6, 2021 (Press release, VBL Therapeutics, MAR 30, 2021, View Source [SID1234577365]). The event will include presentations from Professor Dror Harats, M.D, Chief Executive Officer, Dr. Bradley Monk, M.D., FACS, FACOG, Chair of the OVAL Study Steering Committee, and Dr. Tami Rachmilewitz, M.D, Vice President of Clinical Development, and will focus on the Company’s clinical-stage pipeline including lead program, VB-111. The live event can be accessed at View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Following the event, an archive will be available via the "Events and Presentations" section of the VBL investor relations website at View Source